a92

GCN2-IN-1 (A-92) is an effective GCN2 inhibitor and can be utilized in cancer research as a chemotherapeutic agent.

AA92593 has been used as a selective inhibitor of melanopsin.

Peptide derived from the tumor suppressor protein p16; inhibits cyclin-dependent kinase-4 (cdk4)/cyclin D1 (IC50 ~ 1.5 μM) and binds to cdk6.

Ursolic acid (Prunol) is a natural product, a pentacyclic triterpene carboxylic acid extracted from Rhododendron caprifolium. Ursolic acid has anti-tumor, anti-inflammatory, anti-bacterial and hypoglycemic activities.

CPA 926 is an orally active prodrug of Esculetin that inhibits the production of MMP in cartilage explants. It is applicable for inflammation research, including studies on experimental osteoarthritis.

A 924 is an amino acid derivative with antineoplastic activity.

A 922500 (DGAT-1 Inhibitor 4a) is an inhibitor of human and mouse DGAT-1 with IC50 values of 7 nM and 24 nM, respectively, demonstrating good selectivity over related acyltransferases, hERG, and a panel of anti-targets.

SS148 is an nsp14/nsp16 MTase inhibitor. It also showed some degree of selectivity against human protein MTases, an indication of great potential for chemical optimization towards more potent and selective inhibitors of coronavirus MTases.

Cetuximab (PBS) is a human IgG1 monoclonal antibody that inhibits the epidermal growth factor receptor (EGFR), with a dissociation constant (Kd) of 0.201 nM for EGFR as measured by the SPR method. It exhibits potent antitumor activity.

Anti-Dectin-1 Antibody (2M24) is a humanized IgG1 monoclonal antibody targeting Dectin-1.

IMM-20059 is a humanized IgG1 monoclonal antibody targeting EPN1. When combined with Atezolizumab, IMM-20059 significantly enhances tumor regression in the B16.F10 syngeneic melanoma model compared to anti-PD-L1 monotherapy.

Ramantamig is a humanized monoclonal antibody that targets human CD3ε, GPRC5D, and TNFRSF17 [tumor necrosis factor receptor superfamily member 17]. It holds potential for cancer research, particularly focusing on hematologic malignancies such as multiple myeloma.

Exerenibart is an immunoglobulin G4-κ monoclonal antibody that targets human transmembrane serine protease 6 (TMPRSS6). It shows potential for treating diseases related to iron metabolism disorders, such as iron overload or iron deficiency.

Zemocimig is a human-derived IgG4κ monoclonal antibody that functions as an anticoagulant targeting factor F9.

Besufetamig is a bispecific antibody targeting programmed cell death protein 1 (PD-1) and the CD3ε chain. It modulates immune cell activity, exerting both immunosuppressive and antitumor effects. Besufetamig holds promise for cancer research.

Balekafusp alfa is a human IgG1κ antibody targeting IL-2, known for its antitumor properties.